-
Archives
- December 2017
- June 2017
- May 2017
- February 2017
- November 2016
- October 2016
- September 2016
- July 2016
- April 2016
- March 2016
- December 2015
- August 2015
- April 2015
- February 2015
- January 2015
- December 2014
- November 2014
- September 2014
- August 2014
- July 2014
- May 2014
- January 2014
- December 2013
- November 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
-
Meta
Category Archives: Drug costs
On the Skyrocketing CostsOf MS Drugs: A Patient Point of View
Last week, Daniel M. Hartung, PharmD, MPH, and coauthors, published an open-access article in Neurology on astronomical increases in disease-modifying drugs for multiple sclerosis (MS) –many developed decades ago. Notably, they report that first-generation drugs — now cost about $60,000 … Continue reading
Posted in Drug costs
Tagged Copaxone, generic drugs, multiple sclerosis (MS), preauthorization, specialty pharmacy
Comments Off on On the Skyrocketing CostsOf MS Drugs: A Patient Point of View
Delay of Generics Hurts Consumer,Taxpayer Wallets, and Patient Health
To insure patent extensions of high-priced, blockbuster drugs, brand-name drug companies frequently pay generic drug manufacturers to stay out of the market. It makes cheaper, more affordable generic unavailable for years. The strategy is referred to as “Pay for … Continue reading
Posted in Drug costs
Tagged brand names, Community Catalyst, generic drugs, out-of-pocket costs, Pay-for-Delay, pharma, Supreme Court, Wells Wilkinson
Comments Off on Delay of Generics Hurts Consumer,Taxpayer Wallets, and Patient Health
Why Sanofi’s Zaltrap Deal Won’t Help Patients
I got excited when I read the New York Times story Nov. 9 (“Sanofi Halves Price of Cancer Drug Zaltrap After Sloan-Kettering Rejection)”. Zaltrap is an intravenous infusion drug for metastatic colorectal cancer. It is used for advanced cancer that … Continue reading
Posted in Drug costs
Tagged colon cancer, copays, pharmaceutical companies, Sanofi, value-based healthcare, Zaltrap
1 Comment
When the Pharmaceutical Benefit Manager Won’t Let You Go On Vacation
I leave for vacation in the morning and it was not music to my ears when I heard that the pharmaceutical benefit manager (PBM), the company that reviews your drug use for your health plan or employer, denied an early … Continue reading
Posted in Drug costs, pharmaceutical benefit managers
Tagged mail order, medication therapy management
Comments Off on When the Pharmaceutical Benefit Manager Won’t Let You Go On Vacation
5 Reasons Why I Find This Year’s Allergy Season
Especially Aggravating
1. Allegra, the non-sedating antihistamine has gone over the counter, with nearly psychedelic purple boxes knocking me down when I go into my local drugstore. It has also skyrocketed in cost. That means people with allergies are paying far more … Continue reading
Posted in allergies, cost shifting, Drug costs, OTC drugs
Tagged allergies, drug costs, global warming, OTC drugs
2 Comments
On Disclosure, Transparency, and Firewalls: A Call for Uniform Standards
Since Patient POV was launched March 29, I have been struggling with how to deal with the issue of industry-supported patient advocacy groups. On Thursday, ProPublica released its paper: “Financial Ties Bind Medical Societies to Drug and Device Makers” with … Continue reading